WHAT IS CLAIMED IS:

1. A compound of Formula 1,



1

or a pharmaceutically acceptable salt thereof in which:

(a) X^3 is selected from NR^{3N} and O, X^4 is a single bond, and X^5 is selected from N and CR^5; and

R^1 and R^2, together with the carbon atoms to which they are attached, form a fused ring which is benzene, wherein each non-fusion carbon atom of the fused ring is unsubstituted or is substituted with an optional substituent independently selected from:

(i) halo, hydroxy, and cyano; and

(ii) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo; or

(b) X^3 is CR^{3C}, X^4 is selected from N and CR^4, and X^5 is selected from N and CR^5; and

R^1 and R^2 are each independently selected from:

(i) hydrogen, halo, hydroxy, and cyano; and

(ii) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo; or

R^1 and R^2, together with the carbon atoms to which they are attached, form a fused ring selected from furan, pyrazole, and benzene, wherein one of the nitrogen atoms of the pyrazole ring is substituted with hydrogen, C_{1-4} alkyl or C_{3-6} cycloalkyl, and each non-fusion carbon atom of the fused ring is unsubstituted or is substituted with an optional substituent independently selected from:

(i) halo, hydroxy, and cyano; and

(ii) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo;

L is O and n is 1; or

L is a single bond and n is 0 or 1;

R^{3N} is selected from hydrogen, C_{1-4} alkyl and C_{3-6} cycloalkyl;

R^{3C} and R^4 are each independently selected from:

(i) hydrogen, halo, hydroxy, and cyano; and

(ii) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo;

R^5 is selected from:

(i) hydrogen, halo, hydroxy, and cyano; and

(ii) C_{1-4} alkyl and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo; and

R^6 is hydrogen; or

R^5 and R^6 together form an ethane-1,2-diyl bridging the carbon atoms to which they are attached;

R^7 and R^8 are each independently selected from hydrogen and C_{1-4} alkyl which is substituted with 0 to 3 optional substituents independently selected from halo, wherein at least one of R^7 and R^8 is not hydrogen, or R^7 and R^8, together with the carbon atom to which they are attached, form a C_{3-6} cycloalkylidene;

R^9 is selected from hydrogen and C_{1-4} alkyl which is substituted with 0 to 3 optional substituents independently selected from halo;

R^{10} is selected from azetidin-1-ylmethyl, pyrrolidin-1-ylmethyl, and a heterocyclyl having the formula:



,

in which ~~~ indicates a point of attachment, and

r is selected from 0 and 1;

R^{11} is hydrogen, and R^{12} is selected from hydrogen and from C_{1-4} alkyl and C_{3-6} cycloalkyl, each substituted with 0 to 3 optional substituents independently selected from halo, provided if R^{12} is hydrogen then R^1 and R^2 form a fused ring; or

R^{11} and R^{12} together form a propane-1,3-diyl bridging the carbon and nitrogen atoms to which they are respectively attached;

R^{13}, R^{14}, R^{15}, and R^{16} are each independently selected from hydrogen, halo, and C_{1-4} alkyl which is substituted with 0 to 3 optional substituents independently selected from halo, or R^{13} and R^{16} are absent and R^{14} and R^{15}, together with the carbon atoms to which they are attached, form a fused benzene ring in which each non-fusion carbon atom is unsubstituted or is substituted with an optional substituent independently selected from:

(i) halo, hydroxy, and cyano; and

(ii) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo; and

R^{17} and R^{18} are each independently selected from hydrogen, halo and C_{1-4} alkyl which is substituted with 0 to 3 optional substituents independently selected from halo;

provided the compound of Formula 1 is not:

2-(1-methylpiperidin-2-yl)-*N*-(1-(*m*-tolyl)cyclopropyl)acetamide;

N-(1-(pyridin-3-yl)pentyl)-3-(pyrrolidin-1-yl)propanamide;

N-(1-(6-methylpyridin-2-yl)propan-2-yl)-3-(pyrrolidin-1-yl)propanamide;

2-(1-methylpyrrolidin-2-yl)-*N*-(1-phenylethyl)acetamide;

2-(1-methylpiperidin-2-yl)-*N*-(1-phenylethyl)acetamide;

N-(1-phenylethyl)-3-(pyrrolidin-1-yl)propanamide;

N-(1-(3,4-dichlorophenyl)propyl)-3-(pyrrolidin-1-yl)propanamide;

N-(2-phenylpropan-2-yl)-3-(pyrrolidin-1-yl)propanamide; or

N-(1-(naphthalen-1-yl)ethyl)-2-(pyrrolidin-2-yl)acetamide.

2. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein X^3 is selected from NR^{3N} and O, X^4 is a single bond, and X^5 is selected from N and CR^5.

3. The compound or pharmaceutically acceptable salt thereof according to claim 2, wherein each non-fusion carbon atom of the fused ring formed by R^1 and R^2 is unsubstituted or is substituted with an optional substituent independently selected from halo and C_{1-3} alkyl which is substituted with 0 to 3 optional substituents independently selected from halo.

4. The compound or pharmaceutically acceptable salt thereof according to any one of claims 2 and 3, wherein R^{3N} is C_{1-3} alkyl.

5. The compound or pharmaceutically acceptable salt thereof according to any one of claims 2 to 4, wherein X^3 is selected from NR^{3N} and O, X^4 is a single bond, and X^5 is N.

6. The compound or pharmaceutically acceptable salt thereof according to any one of claims 2 to 5, wherein L is a single bond and n is 0.

7. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein X^3 is CR^{3C}, X^4 is selected from N and CR^4, and X^5 is selected from N and CR^5.

8. The compound or pharmaceutically acceptable salt thereof according to claim 7, wherein R^1 and R^2 are each independently selected from:

(i) hydrogen, halo, hydroxy, and cyano; and

(ii) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo.

9. The compound or pharmaceutically acceptable salt thereof according to claim 7, wherein R^1 and R^2, together with the carbon atoms to which they are attached, form a fused ring selected from furan, pyrazole, and benzene, wherein one of the nitrogen atoms of the pyrazole ring is substituted with hydrogen, C_{1-4} alkyl or C_{3-6} cycloalkyl, and each non-fusion carbon atom of the fused ring is unsubstituted or is substituted with an optional substituent independently selected from:

(i) halo, hydroxy, and cyano; and

(ii) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo.

10. The compound or pharmaceutically acceptable salt thereof according to claim 9, wherein each non-fusion carbon atom of the fused ring formed by R^1 and R^2 is unsubstituted or is substituted with an optional substituent independently selected from halo and C_{1-3} alkyl which is substituted with 0 to 3 optional substituents independently selected from halo.

11. The compound or pharmaceutically acceptable salt thereof according to any one of claims 7 to 10, wherein R^{3C} and R^4 are each independently selected from:

(i) hydrogen and halo; and

(ii) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo.

12. The compound or pharmaceutically acceptable salt thereof according to any one of claims 7 to 11, wherein R^5 is selected from:

(i) hydrogen and halo; and

(ii) C_{1-4} alkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo.

13. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 12, wherein R^7 and R^8 are each independently selected from hydrogen and C_{1-4} alkyl which is substituted with 0 to 3 optional substituents independently selected from halo, wherein at least one of R^7 and R^8 is not hydrogen.

14. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 12, wherein R^7 and R^8, together with the carbon atom to which they are attached, form a cyclopropylidene, cyclobutylidene, and cyclopentylidene.

15. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 14, wherein R^9 is selected from hydrogen, methyl, ethyl, and isopropyl.

16. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 15, wherein R^{10} is azetidin-1-ylmethyl.

17. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 15, wherein R^{10} is pyrrolidin-1-ylmethyl.

18. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 15, wherein R^{10} is a heterocyclyl having the formula:



,

in which ~~~ indicates a point of attachment, and

r is selected from 0 and 1;

R^{11} is hydrogen, and R^{12} is selected from hydrogen and from C_{1-4} alkyl and C_{3-6} cycloalkyl, each substituted with 0 to 3 optional substituents independently selected from halo, provided if R^{12} is hydrogen then R^1 and R^2 form a fused ring; or

R^{11} and R^{12} together form a propane-1,3-diyl bridging the carbon and nitrogen atoms to which they are respectively attached;

R^{13}, R^{14}, R^{15}, and R^{16} are each independently selected from hydrogen, halo, and C_{1-4} alkyl which is substituted with 0 to 3 optional substituents independently selected from halo, or R^{13} and R^{16} are absent and R^{14} and R^{15}, together with the carbon atoms to which they are attached, form a fused benzene ring in which each non-fusion carbon atom is unsubstituted or is substituted with an optional substituent independently selected from:

(i) halo, hydroxy, and cyano; and

(ii) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo; and

R^{17} and R^{18} are each independently selected from hydrogen, halo and C_{1-4} alkyl which is substituted with 0 to 3 optional substituents independently selected from halo.

19. The compound or pharmaceutically acceptable salt thereof according to claim 18, wherein R^{11} is hydrogen, and R^{12} is selected from C_{1-4} alkyl and C_{3-6} cycloalkyl, each substituted with 0 to 3 optional substituents independently selected from halo.

20. The compound or pharmaceutically acceptable salt thereof according to claim 18, wherein R^{11} is hydrogen and R^{12} is selected from methyl, ethyl, isopropyl, and cyclopropyl, each substituted with 0 to 3 optional substituents independently selected from halo.

21. The compound or pharmaceutically acceptable salt thereof according to any one of claims 18 to 20, wherein R^{13}, R^{14}, R^{15}, and R^{16} are each independently selected from hydrogen and methyl.

22. The compound or pharmaceutically acceptable salt thereof according to any one of claims 18 to 21, wherein R^{17} and R^{18} are each independently selected from hydrogen, fluoro and methyl.

23. The compound according to claim 1, which is selected from the following compounds:

N-(2-(1,7-dimethyl-1*H*-indazol-3-yl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

N-(2-(1-methyl-1*H*-indazol-3-yl)propan-2-yl)-2-(1-methylpiperidin-2-yl)acetamide;

(*R*)-*N*-(2-(1-methyl-1*H*-indazol-3-yl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-(1-methyl-1*H*-indazol-3-yl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

N-(2-(isoquinolin-1-yl)propan-2-yl)-3-(pyrrolidin-1-yl)propanamide;

N-(2-(isoquinolin-1-yl)propan-2-yl)-2-(1-methylpiperidin-2-yl)acetamide;

N-(2-(5-methylisoquinolin-1-yl)propan-2-yl)-2-(1-methylpiperidin-2-yl)acetamide;

(*R*)-*N*-(2-(5-methylisoquinolin-1-yl)propan-2-yl)-2-(1-methylpiperidin-2-yl)acetamide;

(*S*)-*N*-(2-(5-methylisoquinolin-1-yl)propan-2-yl)-2-(1-methylpiperidin-2-yl)acetamide;

N-(2-(1-methyl-1*H*-indazol-3-yl)propan-2-yl)-2-(tetrahydro-1*H*-pyrrolizin-7a(5*H*)-yl)acetamide;

N-(2-(3-chlorophenyl)propan-2-yl)-2-(1-methylpiperidin-2-yl)acetamide;

N-(2-(3-chlorophenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

N-(2-(furo[3,2-*c*]pyridin-4-yl)propan-2-yl)-2-(1-methylpiperidin-2-yl)acetamide;

(*R*)-*N*-(2-(furo[3,2-*c*]pyridin-4-yl)propan-2-yl)-2-(1-methylpiperidin-2-yl)acetamide;

(*S*)-*N*-(2-(furo[3,2-*c*]pyridin-4-yl)propan-2-yl)-2-(1-methylpiperidin-2-yl)acetamide;

(*R*)-*N*-(2-(isoquinolin-1-yl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*R*)-*N*-(2-(5-methylisoquinolin-1-yl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-(5-methylisoquinolin-1-yl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*R*)-*N*-(2-(7-methylbenzo[*d*]isoxazol-3-yl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-(isoquinolin-1-yl)propan-2-yl)-2-(2-methyl-1,2,3,4-tetrahydroisoquinolin-3-yl)acetamide;

(*S*)-*N*-(2-(7-methylbenzo[d]isoxazol-3-yl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-(3-methylisoquinolin-1-yl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-(isoquinolin-1-yl)propan-2-yl)-2-(pyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-(isoquinolin-1-yl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

N-(2-(furo[3,2-*c*]pyridin-4-yl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

N-(2-(1-methyl-1*H*-pyrazolo[4,3-*c*]pyridin-4-yl)propan-2-yl)-2-(1-methylpiperidin-2-yl)acetamide;

2-(1-ethylpyrrolidin-2-yl)-*N*-(2-(furo[3,2-*c*]pyridin-4-yl)propan-2-yl)acetamide;

N-(2-methyl-1-((3-(trifluoromethyl)pyridin-2-yl)oxy)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

N-(2-methyl-1-((3-(trifluoromethyl)pyridin-2-yl)oxy)propan-2-yl)-2-(1-methylpiperidin-2-yl)acetamide;

N-(2-(4-chlorophenyl)propan-2-yl)-2-(1-methylpiperidin-2-yl)acetamide;

N-((*S*)-1-(4-chlorophenyl)ethyl)-2-((*S*)-1-methylpyrrolidin-2-yl)acetamide;

N-((*S*)-1-(4-fluorophenyl)ethyl)-2-((*S*)-1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-(2,5-dichlorophenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-(furo[3,2-*c*]pyridin-4-yl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-(4-chlorophenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

N-((*S*)-1-(4-chlorophenyl)ethyl)-2-((*R*)-1-methylpyrrolidin-2-yl)acetamide;

N-((*S*)-1-(4-fluorophenyl)ethyl)-2-((*R*)-1-methylpyrrolidin-2-yl)acetamide;

(*R*)-*N*-(2-(2,5-dichlorophenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*R*)-*N*-(2-(furo[3,2-*c*]pyridin-4-yl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*R*)-*N*-(2-(4-chlorophenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

N-(2-(7-methylbenzo[*d*]isoxazol-3-yl)propan-2-yl)-2-(1-methylpiperidin-2-yl)acetamide;

N-(2-(4-methylisoquinolin-1-yl)propan-2-yl)-2-(1-methylpiperidin-2-yl)acetamide;

(*R*)-*N*-(2-(7-methylbenzo[*d*]isoxazol-3-yl)propan-2-yl)-2-(1-methylpiperidin-2-yl)acetamide;

(*S*)-*N*-(2-(7-methylbenzo[*d*]isoxazol-3-yl)propan-2-yl)-2-(1-methylpiperidin-2-yl)acetamide;

N-(2-(2,5-dichlorophenyl)propan-2-yl)-2-(1-methylpiperidin-2-yl)acetamide;

(*R*)-*N*-(2-methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-methyl-1-((3-(trifluoromethyl)pyridin-2-yl)oxy)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*R*)-*N*-(2-methyl-1-((3-(trifluoromethyl)pyridin-2-yl)oxy)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

2-(1-ethylpyrrolidin-2-yl)-*N*-(2-methyl-1-((3-(trifluoromethyl)pyridin-2-yl)oxy)propan-2-yl)acetamide;

(*S*)-2-(1-ethylpyrrolidin-2-yl)-*N*-(2-methyl-1-((3-(trifluoromethyl)pyridin-2-yl)oxy)propan-2-yl)acetamide;

(*S*)-2-(1-(2-fluoroethyl)pyrrolidin-2-yl)-*N*-(2-methyl-1-((3-(trifluoromethyl)pyridin-2-yl)oxy)propan-2-yl)acetamide;

(*S*)-2-(1-cyclopropylpyrrolidin-2-yl)-*N*-(2-methyl-1-((3-(trifluoromethyl)pyridin-2-yl)oxy)propan-2-yl)acetamide;

(*S*)-*N*-(1-(((3-methylpyridin-2-yl)oxy)methyl)cyclopropyl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(1-(((3-methylpyridin-2-yl)oxy)methyl)cyclobutyl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(1-(((3-methylpyridin-2-yl)oxy)methyl)cyclopentyl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*R*)-2-(1-ethylpyrrolidin-2-yl)-*N*-(2-methyl-1-((3-(trifluoromethyl)pyridin-2-yl)oxy)propan-2-yl)acetamide;

(*R*)-2-(1-(2-fluoroethyl)pyrrolidin-2-yl)-*N*-(2-methyl-1-((3-(trifluoromethyl)pyridin-2-yl)oxy)propan-2-yl)acetamide;

(*R*)-2-(1-cyclopropylpyrrolidin-2-yl)-*N*-(2-methyl-1-((3-(trifluoromethyl)pyridin-2-yl)oxy)propan-2-yl)acetamide;

N-((*S*)-1-(4-chlorophenyl)ethyl)-2-(1-methylpiperidin-2-yl)acetamide;

N-((*S*)-1-(4-fluorophenyl)ethyl)-2-(1-methylpiperidin-2-yl)acetamide;

2-(1-ethylpyrrolidin-2-yl)-*N*-(2-methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)acetamide;

2-(1-ethylpyrrolidin-2-yl)-*N*-(1-(((3-methylpyridin-2-yl)oxy)methyl)cyclopropyl)acetamide;

2-(1-ethylpyrrolidin-2-yl)-*N*-(1-(((3-methylpyridin-2-yl)oxy)methyl)cyclobutyl)acetamide;

2-(1-ethylpyrrolidin-2-yl)-*N*-(1-(((3-methylpyridin-2-yl)oxy)methyl)cyclopentyl)acetamide;

(*R*)-*N*-(2-methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-2-((*S*)-1-methylpyrrolidin-2-yl)propanamide;

(*S*)-*N*-(2-methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-2-((*R*)-1-methylpyrrolidin-2-yl)propanamide;

(*S*)-*N*-(2-methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-2-((*S*)-1-methylpyrrolidin-2-yl)propanamide;

(*R*)-*N*-(2-methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-2-((*R*)-1-methylpyrrolidin-2-yl)propanamide;

2-(1,5-dimethylpyrrolidin-2-yl)-*N*-(2-methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)acetamide;

N-(2-methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-2-(1-methylpiperidin-2-yl)acetamide;

(*R*)-*N*-(2-(3-methylisoquinolin-1-yl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

N-(1-(((3-methylpyridin-2-yl)oxy)methyl)cyclopropyl)-2-(1-methylpyrrolidin-2-yl)propanamide;

(*S*)-*N*-(2-methyl-1-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(1-((3-cyclopropylpyridin-2-yl)oxy)-2-methylpropan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

N-(1-(2-methoxybenzyl)cyclopropyl)-2-(1-methylpiperidin-2-yl)acetamide;

(*R*)-*N*-(2-(2-methoxyphenyl)propan-2-yl)-2-methyl-3-(pyrrolidin-1-yl)propanamide;

(*S*)-*N*-(2-(2-methoxyphenyl)propan-2-yl)-2-methyl-3-(pyrrolidin-1-yl)propanamide;

N-(2-methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-2-(tetrahydro-1*H*-pyrrolizin-7a(5*H*)-yl)acetamide;

N-(1-((3-(difluoromethyl)pyridin-2-yl)oxy)-2-methylpropan-2-yl)-2-(tetrahydro-1*H*-pyrrolizin-7a(5*H*)-yl)acetamide;

N-(1-((2-methoxypyridin-3-yl)methyl)cyclopropyl)-2-(1-methylpiperidin-2-yl)acetamide;

(*S*)-*N*-(2-(2,3-dichlorophenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(1-(3-methylbenzyl)cyclopropyl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-(2,3-difluorophenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-(3-chloro-2-fluorophenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*R*)-*N*-(1-((3-(difluoromethyl)pyridin-2-yl)oxy)-2-methylpropan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(1-((3-(difluoromethyl)pyridin-2-yl)oxy)-2-methylpropan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-(2-fluoro-3-methylphenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*R*)-*N*-(2-(2-fluoro-3-methylphenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-(2-chloro-3-methylphenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-(3-fluoro-2-methylphenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*R*)-*N*-(2-(3-fluoro-2-methylphenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*R*)-*N*-(2-(2-chloro-3-methylphenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-(2,3-dimethylphenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-(2-chloro-3-fluorophenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*R*)-*N*-(2-(2-chloro-3-fluorophenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

N-((*S*)-1-(4-fluoro-2-methoxyphenyl)ethyl)-2-((*S*)-1-methylpyrrolidin-2-yl)acetamide;

(*R*)-*N*-(2-(2,3-dichlorophenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

2-(3,3-difluoro-1-methylpyrrolidin-2-yl)-*N*-(2-(isoquinolin-1-yl)propan-2-yl)acetamide;

2-(3,3-difluoro-1-methylpyrrolidin-2-yl)-*N*-(2-(5-methylisoquinolin-1-yl)propan-2-yl)acetamide;

2-(3,3-difluoro-1-methylpyrrolidin-2-yl)-*N*-(2-(furo[3,2-*c*]pyridin-4-yl)propan-2-yl)acetamide;

2-(3,3-difluoropyrrolidin-2-yl)-*N*-(2-(isoquinolin-1-yl)propan-2-yl)acetamide;

2-(3,3-difluoropyrrolidin-2-yl)-*N*-(2-(5-methylisoquinolin-1-yl)propan-2-yl)acetamide;

(*S*)-*N*-(2-methyl-1-((4-methylpyridin-2-yl)oxy)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-methyl-1-((5-methylpyridin-2-yl)oxy)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-methyl-1-((6-methylpyridin-2-yl)oxy)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(1-((4-chloro-5-fluoropyridin-2-yl)oxy)-2-methylpropan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*R*)-*N*-(2-methyl-1-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*R*)-*N*-(1-((3-ethoxypyridin-2-yl)oxy)-2-methylpropan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*R*)-*N*-(1-((3-cyclopropylpyridin-2-yl)oxy)-2-methylpropan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(1-((3-ethoxypyridin-2-yl)oxy)-2-methylpropan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*R*)-*N*-(2-(isoquinolin-1-yl)propan-2-yl)-2-((*S*)-1-methylpyrrolidin-2-yl)propanamide:

(*S*)-*N*-(2-(isoquinolin-1-yl)propan-2-yl)-2-((*R*)-1-methylpyrrolidin-2-yl)propanamide;

(*R*)-*N*-(2-(isoquinolin-1-yl)propan-2-yl)-2-((*R*)-1-methylpyrrolidin-2-yl)propanamide;

(*S*)-*N*-(2-(isoquinolin-1-yl)propan-2-yl)-2-((*S*)-1-methylpyrrolidin-2-yl)propanamide;

(*S*)-*N*-(2-(3-chloro-2-methoxyphenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*R*)-*N*-(2-(3-chloro-2-methoxyphenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-(3-fluoro-2-methoxyphenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*R*)-*N*-(2-(3-fluoro-2-methoxyphenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-(2-methoxy-3-methylphenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*R*)-*N*-(2-(2-methoxy-3-methylphenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-(3-chloro-2-methylphenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*R*)-*N*-(2-(3-chloro-2-methylphenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

2-(1-methylpiperidin-2-yl)-*N*-(1-(((3-methylpyridin-2-yl)oxy)methyl)cyclopropyl)acetamide;

(*R*)-*N*-(1-(((3-methylpyridin-2-yl)oxy)methyl)cyclopropyl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(1-(furo[2,3-*c*]pyridin-7-yloxy)-2-methylpropan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(2-methyl-1-(pyridin-2-yloxy)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(1-((3-chloro-5-methylpyridin-2-yl)oxy)-2-methylpropan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(1-(furo[3,2-*c*]pyridin-4-yloxy)-2-methylpropan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;

(*S*)-*N*-(1-(((3-methylpyridin-2-yl)oxy)methyl)cyclopropyl)-2-((*R*)-1-methylpyrrolidin-2-yl)propanamide;

(*R*)-*N*-(1-(((3-methylpyridin-2-yl)oxy)methyl)cyclopropyl)-2-((*S*)-1-methylpyrrolidin-2-yl)propanamide;

N-(2-((*S*)-chroman-2-yl)propan-2-yl)-2-((*S*)-1-methylpyrrolidin-2-yl)acetamide;

N-(2-((*R*)-chroman-2-yl)propan-2-yl)-2-((*S*)-1-methylpyrrolidin-2-yl)acetamide;

N-(2-((*R*)-chroman-2-yl)propan-2-yl)-2-((*R*)-1-methylpyrrolidin-2-yl)acetamide;

N-(2-((*S*)-chroman-2-yl)propan-2-yl)-2-((*R*)-1-methylpyrrolidin-2-yl)acetamide;

3-(azetidin-1-yl)-*N*-(2-(2-chlorophenyl)propan-2-yl)-2-methylpropanamide;

(*R*)-3-(azetidin-1-yl)-*N*-(2-(2-chlorophenyl)propan-2-yl)-2-methylpropanamide;

(*S*)-3-(azetidin-1-yl)-*N*-(2-(2-chlorophenyl)propan-2-yl)-2-methylpropanamide;

N-(2-(2-chlorophenyl)propan-2-yl)-2-methyl-3-(pyrrolidin-1-yl)propanamide;

(*R*)-*N*-(2-(2-chlorophenyl)propan-2-yl)-2-methyl-3-(pyrrolidin-1-yl)propanamide;

(*S*)-*N*-(2-(2-chlorophenyl)propan-2-yl)-2-methyl-3-(pyrrolidin-1-yl)propanamide;

(*R*)-3-(azetidin-1-yl)-*N*-(2-(4-methoxyphenyl)propan-2-yl)-2-methylpropanamide;

(*S*)-3-(azetidin-1-yl)-*N*-(2-(4-methoxyphenyl)propan-2-yl)-2-methylpropanamide;
(*R*)-3-(azetidin-1-yl)-2-methyl-*N*-(2-(*o*-tolyl)propan-2-yl)propanamide;
(*S*)-3-(azetidin-1-yl)-2-methyl-*N*-(2-(*o*-tolyl)propan-2-yl)propanamide;
(*R*)-3-(azetidin-1-yl)-*N*-(2-(3-fluoro-2-methylphenyl)propan-2-yl)-2-methylpropanamide;
(*S*)-3-(azetidin-1-yl)-*N*-(2-(3-fluoro-2-methylphenyl)propan-2-yl)-2-methylpropanamide;
(*R*)-3-(azetidin-1-yl)-*N*-(2-(2-chloro-3-methylphenyl)propan-2-yl)-2-methylpropanamide;
(*S*)-3-(azetidin-1-yl)-*N*-(2-(2-chloro-3-methylphenyl)propan-2-yl)-2-methylpropanamide;
(*R*)-3-(azetidin-1-yl)-*N*-(2-(2-methoxy-3-methylphenyl)propan-2-yl)-2-methylpropanamide;
(*S*)-3-(azetidin-1-yl)-*N*-(2-(2-methoxy-3-methylphenyl)propan-2-yl)-2-methylpropanamide;
(*R*)-3-(azetidin-1-yl)-2-methyl-*N*-(2-(*p*-tolyl)propan-2-yl)propanamide;
(*S*)-3-(azetidin-1-yl)-2-methyl-*N*-(2-(*p*-tolyl)propan-2-yl)propanamide;
(*R*)-3-(azetidin-1-yl)-*N*-(1-(2-fluorophenyl)cyclopropyl)-2-methylpropanamide;
(*S*)-3-(azetidin-1-yl)-*N*-(1-(2-fluorophenyl)cyclopropyl)-2-methylpropanamide;
(*R*)-3-(azetidin-1-yl)-*N*-(2-(3-fluorophenyl)propan-2-yl)-2-methylpropanamide;
(*S*)-3-(azetidin-1-yl)-*N*-(2-(3-fluorophenyl)propan-2-yl)-2-methylpropanamide;
(*R*)-3-(azetidin-1-yl)-*N*-(2-(4-chlorophenyl)propan-2-yl)-2-methylpropanamide;
(*S*)-3-(azetidin-1-yl)-*N*-(2-(4-chlorophenyl)propan-2-yl)-2-methylpropanamide;
(*R*)-3-(azetidin-1-yl)-*N*-(2-(2-fluorophenyl)propan-2-yl)-2-methylpropanamide;
(*S*)-3-(azetidin-1-yl)-*N*-(2-(2-fluorophenyl)propan-2-yl)-2-methylpropanamide;
2-((*S*)-1-methylpyrrolidin-2-yl)-*N*-(2,2,2-trifluoro-1-(*p*-tolyl)ethyl)acetamide;
(*R*)-*N*-(2-(2-fluorophenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;
(*S*)-*N*-(2-(2-fluorophenyl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;
3-(azetidin-1-yl)-*N*-(2-(2-chloro-3-methylphenyl)propan-2-yl)propanamide;
3-(azetidin-1-yl)-*N*-(2-(*m*-tolyl)propan-2-yl)propanamide;
3-(azetidin-1-yl)-*N*-(2-(3-fluorophenyl)propan-2-yl)propanamide;
3-(azetidin-1-yl)-*N*-(2-(3-chlorophenyl)propan-2-yl)propanamide;
3-(azetidin-1-yl)-*N*-(2-(4-chlorophenyl)propan-2-yl)propanamide;

3-(azetidin-1-yl)-*N*-(2-(3-fluoro-2-methylphenyl)propan-2-yl)propanamide;

3-(azetidin-1-yl)-*N*-(1-(2,5-difluorophenyl)-2,2-difluoroethyl)propanamide;

(*S*)-3-(azetidin-1-yl)-*N*-(1-(2,5-difluorophenyl)-2,2-difluoroethyl)propanamide;

(*R*)-3-(azetidin-1-yl)-*N*-(1-(2,5-difluorophenyl)-2,2-difluoroethyl)propanamide;

3-(azetidin-1-yl)-*N*-(2-(3-fluoro-2-methoxyphenyl)propan-2-yl)-2-methylpropanamide;

(*R*)-3-(azetidin-1-yl)-*N*-(2-(3-fluoro-2-methoxyphenyl)propan-2-yl)-2-methylpropanamide;

(*S*)-3-(azetidin-1-yl)-*N*-(2-(3-fluoro-2-methoxyphenyl)propan-2-yl)-2-methylpropanamide;

3-(azetidin-1-yl)-*N*-(2-fluoro-1-(*p*-tolyl)ethyl)propanamide;

(*S*)-3-(azetidin-1-yl)-*N*-(2-fluoro-1-(*p*-tolyl)ethyl)propanamide;

(*R*)-3-(azetidin-1-yl)-*N*-(2-fluoro-1-(*p*-tolyl)ethyl)propanamide;

(*S*)-*N*-(1-(((3-methylpyridin-2-yl)oxy)methyl)cyclopropyl)-2-((*S*)-1-methylpyrrolidin-2-yl)propanamide;

(*R*)-*N*-(1-(((3-methylpyridin-2-yl)oxy)methyl)cyclopropyl)-2-((*R*)-1-methylpyrrolidin-2-yl)propanamide;

(*S*)-2-(azetidin-1-ylmethyl)-*N*-((*S*)-2,2-difluoro-1-phenylethyl)-3-methylbutanamide;

(*S*)-2-(azetidin-1-ylmethyl)-*N*-((*R*)-2,2-difluoro-1-phenylethyl)-3-methylbutanamide;

(*S*)-2-(azetidin-1-ylmethyl)-*N*-((*R*)-2,2-difluoro-1-phenylethyl)butanamide;

(*R*)-3-(azetidin-1-yl)-*N*-((*R*)-2,2-difluoro-1-phenylethyl)-2-methylpropanamide;

(*R*)-2-(azetidin-1-ylmethyl)-*N*-(2-(4-fluorophenyl)propan-2-yl)butanamide;

(*S*)-2-(azetidin-1-ylmethyl)-*N*-(2-(4-fluorophenyl)propan-2-yl)butanamide;

(*R*)-2-(azetidin-1-ylmethyl)-*N*-(2-(3-fluorophenyl)propan-2-yl)butanamide;

(*S*)-2-(azetidin-1-ylmethyl)-*N*-(2-(3-fluorophenyl)propan-2-yl)butanamide;

(*R*)-2-(azetidin-1-ylmethyl)-*N*-(2-(*p*-tolyl)propan-2-yl)butanamide;

(*S*)-2-(azetidin-1-ylmethyl)-*N*-(2-(*p*-tolyl)propan-2-yl)butanamide;

(*S*)-2-(azetidin-1-ylmethyl)-*N*-((*R*)-2,2-difluoro-1-(2-methoxyphenyl)ethyl)-3-methylbutanamide ;

(*S*)-2-(azetidin-1-ylmethyl)-*N*-((*R*)-2,2-difluoro-1-(2-methoxyphenyl)ethyl)butanamide;

(*S*)-3-(azetidin-1-yl)-*N*-(2,2,2-trifluoro-1-(4-fluorophenyl)ethyl)propanamide;

(*S*)-3-(azetidin-1-yl)-*N*-(1-(3-chlorophenyl)-2,2,2-trifluoroethyl)propanamide;

(*R*)-3-(azetidin-1-yl)-*N*-(1-(3-chlorophenyl)-2,2,2-trifluoroethyl)propanamide;
(*R*)-3-(azetidin-1-yl)-*N*-(2,2,2-trifluoro-1-(3-fluorophenyl)ethyl)propanamide;
(*S*)-2-(azetidin-1-ylmethyl)-*N*-((*R*)-2,2-difluoro-1-(3-fluorophenyl)ethyl)-3-methylbutanamide;
(*S*)-2-(azetidin-1-ylmethyl)-*N*-((*R*)-2,2-difluoro-1-(3-fluorophenyl)ethyl)butanamide;
(*S*)-2-(azetidin-1-ylmethyl)-*N*-((*R*)-2,2-difluoro-1-(4-fluorophenyl)ethyl)-3-methylbutanamide;
(*S*)-*N*-(1-(3-chlorophenyl)-2,2-difluoroethyl)-3-(pyrrolidin-1-yl)propanamide;
(*R*)-*N*-(1-(3-chlorophenyl)-2,2-difluoroethyl)-3-(pyrrolidin-1-yl)propanamide;
(*R*)-2-(azetidin-1-ylmethyl)-*N*-(2-(2-fluorophenyl)propan-2-yl)butanamide;
(*S*)-2-(azetidin-1-ylmethyl)-*N*-(2-(2-fluorophenyl)propan-2-yl)butanamide;
(*R*)-3-(azetidin-1-yl)-*N*-(2,2-difluoro-1-phenylethyl)propanamide;
(*R*)-3-(azetidin-1-yl)-*N*-(1-(3-chlorophenyl)-2,2-difluoroethyl)propanamide;
N-(2-(isoquinolin-1-yl)propan-2-yl)-2-(1-methylpyrrolidin-2-yl)acetamide;
(*S*)-2-(azetidin-1-ylmethyl)-*N*-((*R*)-2,2-difluoro-1-(4-fluorophenyl)ethyl)butanamide;
(*R*)-3-(azetidin-1-yl)-*N*-((*R*)-2-fluoro-1-phenylethyl)-2-methylpropanamide;
(*S*)-3-(azetidin-1-yl)-*N*-((*R*)-2-fluoro-1-phenylethyl)-2-methylpropanamide;
(*S*)-3-(azetidin-1-yl)-*N*-(2,2,2-trifluoro-1-(*p*-tolyl)ethyl)propanamide;
(*S*)-3-(azetidin-1-yl)-*N*-(2,2,2-trifluoro-1-(3-fluorophenyl)ethyl)propanamide;
(*S*)-3-(azetidin-1-yl)-*N*-(2,2,2-trifluoro-1-(2-fluorophenyl)ethyl)propanamide;
(*S*)-3-(azetidin-1-yl)-*N*-(2,2,2-trifluoro-1-(*o*-tolyl)ethyl)propanamide; and
a pharmaceutically acceptable salt of any one of the aforementioned compounds.

24. A pharmaceutical composition comprising:
a compound or pharmaceutically acceptable salt as defined in any one of claims 1 to 23; and
a pharmaceutically acceptable excipient.

25. A compound or pharmaceutically acceptable salt as defined in any one of claims 1 to 23 for use as a medicament.

26. A compound or pharmaceutically acceptable salt as defined in any one of claims 1 to 23 for use in the treatment of a disease, disorder or condition selected from Alzheimer's disease, depression, anxiety, schizophrenia, bipolar disorder, autism, epilepsy, pain, and hyperactivity disorder.

27. Use of a compound or pharmaceutically acceptable salt as defined in any one of claims 1 to 23, in the manufacture of a medicament for treating a disease, disorder or condition in a subject, wherein the disease, disorder or condition is selected from Alzheimer's disease, depression, anxiety, schizophrenia, bipolar disorder, autism, epilepsy, pain, and hyperactivity disorder.

28. A combination comprising a compound or pharmaceutically acceptable salt as defined in any one of claims 1 to 23, and at least one additional pharmacologically active agent.

29. The combination according to claim 28, wherein the additional pharmacologically active agent is selected from beta-secretase inhibitors, gamma-secretase inhibitors, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs, vitamin E, anti-amyloid antibodies, antidepressants, antipsychotics, anxiolytics, and anticonvulsants.

30. A compound of Formula 1,



1

or a pharmaceutically acceptable salt thereof for use as a medicament in which:

(a) X^3 is selected from NR^{3N} and O, X^4 is a single bond, and X^5 is selected from N and CR^5; and

R^1 and R^2, together with the carbon atoms to which they are attached, form a fused ring which is benzene, wherein each non-fusion carbon atom of the fused ring is unsubstituted or is substituted with an optional substituent independently selected from:

(i) halo, hydroxy, and cyano; and

(ii) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo; or

(b) X^3 is CR^{3C}, X^4 is selected from N and CR^4, and X^5 is selected from N and CR^5; and

R^1 and R^2 are each independently selected from:

(i) hydrogen, halo, hydroxy, and cyano; and

(ii) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo; or

R^1 and R^2, together with the carbon atoms to which they are attached, form a fused ring selected from furan, pyrazole, and benzene, wherein one of the nitrogen atoms of the pyrazole ring is substituted with hydrogen, C_{1-4} alkyl or C_{3-6} cycloalkyl, and each non-fusion carbon atom of the fused ring is unsubstituted or is substituted with an optional substituent independently selected from:

(i) halo, hydroxy, and cyano; and

(ii) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo;

L is O and n is 1; or

L is a single bond and n is 0 or 1;

R^{3N} is selected from hydrogen, C_{1-4} alkyl and C_{3-6} cycloalkyl;

R^{3C} and R^4 are each independently selected from:

(i) hydrogen, halo, hydroxy, and cyano; and

(ii) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo;

R^5 is selected from:

(i) hydrogen, halo, hydroxy, and cyano; and

(ii) C_{1-4} alkyl and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo; and

R^6 is hydrogen; or

R^5 and R^6 together form an ethane-1,2-diyl bridging the carbon atoms to which they are attached;

R^7 and R^8 are each independently selected from hydrogen and C_{1-4} alkyl which is substituted with 0 to 3 optional substituents independently selected from halo, wherein at least one of R^7 and R^8 is not hydrogen, or R^7 and R^8, together with the carbon atom to which they are attached, form a C_{3-6} cycloalkylidene;

R^9 is selected from hydrogen and C_{1-4} alkyl which is substituted with 0 to 3 optional substituents independently selected from halo;

R^{10} is selected from azetidin-1-ylmethyl, pyrrolidin-1-ylmethyl, and a heterocyclyl having the formula:



,

in which ~~~ indicates a point of attachment, and

r is selected from 0 and 1;

R^{11} is hydrogen, and R^{12} is selected from hydrogen and from C_{1-4} alkyl and C_{3-6} cycloalkyl, each substituted with 0 to 3 optional substituents independently selected from halo, provided if R^{12} is hydrogen then R^1 and R^2 form a fused ring; or

R^{11} and R^{12} together form a propane-1,3-diyl bridging the carbon and nitrogen atoms to which they are respectively attached;

R^{13}, R^{14}, R^{15}, and R^{16} are each independently selected from hydrogen, halo, and C_{1-4} alkyl which is substituted with 0 to 3 optional substituents independently selected from halo, or R^{13} and R^{16} are absent and R^{14} and R^{15}, together with the carbon atoms to which they are attached, form a fused benzene ring in which each non-fusion carbon atom is unsubstituted or is substituted with an optional substituent independently selected from:

(i) halo, hydroxy, and cyano; and

(ii) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo; and

R^{17} and R^{18} are each independently selected from hydrogen, halo and C_{1-4} alkyl which is substituted with 0 to 3 optional substituents independently selected from halo;

provided the compound of Formula 1 is not:

N-(1-phenylethyl)-3-(pyrrolidin-1-yl)propanamide; or

N-(1-(3,4-dichlorophenyl)propyl)-3-(pyrrolidin-1-yl)propanamide.

31. A pharmaceutical composition comprising:

a compound or pharmaceutically acceptable salt as defined in claim 30; and

a pharmaceutically acceptable excipient.

32. A compound or pharmaceutically acceptable salt as defined in claim 30 for use in the treatment of a disease, disorder or condition selected from Alzheimer's disease, depression, anxiety, schizophrenia, bipolar disorder, autism, epilepsy, pain, and hyperactivity disorder.

33. Use of a compound or pharmaceutically acceptable salt as defined in claim 30, in the manufacture of a medicament for treating a disease, disorder or condition in a subject, wherein the disease, disorder or condition is selected from Alzheimer's disease, depression, anxiety, schizophrenia, bipolar disorder, autism, epilepsy, pain, and hyperactivity disorder.

34. A combination comprising a compound or pharmaceutically acceptable salt as defined in claim 30, and at least one additional pharmacologically active agent.

35. The combination according to claim 34, wherein the additional pharmacologically active agent is selected from beta-secretase inhibitors, gamma-secretase inhibitors, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs, vitamin E, anti-amyloid antibodies, antidepressants, antipsychotics, anxiolytics, and anticonvulsants.